THE IMPORTANCE OF BIOMARKERS IN THE EARLY DETECTION OF CANCER

Noyabr, 2025-Yil 125 THE IMPORTANCE OF BIOMARKERS IN THE EARLY DETECTION OF CANCER ¹Bahritdinova Iroda Mirzabek qizi ²G’ofurova Feruza Farxodovna; ³Madaminova Sevaraxon Muxammadjon qizi ¹²³Department of General Oncology, Samarkand State Medical University https://doi.org/10.5281/zenodo.17584197 Introduction Cancer remains one of the leading causes of mortality worldwide, and early detection plays a crucial role in improving patient survival rates. Traditional diagnostic methods, such as imaging and histopathology, often detect cancer only after it has advanced, reducing treatment effectiveness. Biomarkers—biological molecules found in blood, body fluids, or tissues—offer a promising alternative for early diagnosis. They can indicate abnormal cellular processes or tumor formation before clinical symptoms appear. Advances in molecular biology and genomics have led to the identification of numerous biomarkers that enable early screening, precise diagnosis, and monitoring of therapeutic responses. Malignant neoplasms continue to pose a significant global health burden, with rising incidence and mortality rates. Delayed identification often results in limited therapeutic options and poor prognoses. Conventional diagnostic approaches, including radiological imaging, histological examination, and physical assessment, frequently detect tumors only at advanced stages. In this context, molecular biomarkers have emerged as essential tools for early recognition of oncological disorders. These indicators, detectable in biological specimens such as blood, urine, or tissue, reflect underlying pathological changes before clinical manifestations become evident. Recent technological progress in genomics, proteomics, and metabolomics has enabled the discovery of novel molecular signatures, facilitating precision screening and personalized intervention strategies. Identification of specific biomarkers allows clinicians to stratify patients according to risk, monitor disease progression, and evaluate therapeutic efficacy in real time. Objective: The main objective of this study is to evaluate the role and significance of cancer biomarkers in early diagnosis, to analyze their diagnostic accuracy, and to determine how their use can improve patient outcomes through timely intervention. Materials and Methods: A systematic review of literature published between 2015 and 2024 was conducted using databases such as PubMed, Scopus, and Web of Science. Studies focusing on serum, genetic, and protein biomarkers associated with common cancers—including breast, lung, prostate, and colorectal—were included. Data extraction focused on biomarker sensitivity, specificity, and correlation with early cancer stages. Analytical and statistical evaluations were performed to determine diagnostic reliability. Results: Analysis of over 70 studies demonstrated that certain biomarkers, such as PSA for prostate cancer, CA-125 for ovarian cancer, CEA for colorectal cancer, and circulating tumor DNA (ctDNA) for various cancers, showed high diagnostic sensitivity in early stages. Noyabr, 2025-Yil 126 Combining multiple biomarkers significantly increased diagnostic accuracy and reduced false-positive results. Genetic and epigenetic biomarkers, including miRNAs and methylation patterns, provided additional insights into early tumor development and progression. Comprehensive analysis of contemporary research highlighted numerous molecular candidates exhibiting high predictive value for initial tumor development. Prostate-specific antigens demonstrated early detection capability in urological malignancies, while carbohydrateassociated proteins offered diagnostic support in gynecologic cancers. Circulating nucleic acids, including fragmented DNA and microRNAs, provided a minimally invasive approach to detect molecular alterations prior to anatomical changes. Multimarker panels consistently outperformed single analytes, enhancing both sensitivity and specificity, and minimizing the probability of erroneous classification. Comparative evaluation revealed that integrating proteomic, genomic, and epigenetic markers improved identification of latent neoplasms and enabled differentiation between benign and malignant lesions. Discussion: The cumulative findings emphasize the transformative potential of biomarkers in oncology practice. Employing these molecular indicators for population screening can reduce diagnostic delays, guide individualized treatment regimens, and optimize clinical outcomes. Challenges remain in standardization, validation, and cost-effective implementation of biomarker assays. Moreover, heterogeneity among tumor types necessitates tailored approaches for each cancer category. Ethical considerations, data interpretation, and integration with existing diagnostic workflows are critical to maximize clinical benefit. Future investigations focusing on longitudinal cohort studies and large-scale clinical trials are essential to establish robust evidence supporting routine biomarker utilization. Conclusion: Biomarkers represent a critical advancement in the early detection of cancer, offering noninvasive, cost-effective, and rapid diagnostic possibilities. Their integration into routine screening programs can lead to earlier diagnosis, better treatment planning, and improved survival outcomes. Further research and standardization of biomarker testing methods are essential to enhance their clinical applicability and ensure consistent diagnostic precision across different cancer types. Biomarker-based detection strategies signify a paradigm shift in modern oncology by enabling identification of malignancies at an incipient phase. Their application enhances early intervention, personalized management, and long-term survival prospects. Establishing standardized protocols, expanding analytical capabilities, and promoting multidisciplinary collaboration are imperative to fully harness their potential and transform cancer diagnostics into a proactive rather than reactive practice. References: 1. БЕЛКА, F. S. Р. С. Р. (2022). В ПАТОГЕНЕЗЕ СОСУДИСТЫХ ЗАБОЛЕВАНИЙ ОРГАНА ЗРЕНИЯ У БОЛЬНЫХ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ. 2. Жалалова, Д. З., Кадирова, А. М., & Хамракулов, С. Б. (2021). Исходы герпетических кератоувеитов на фоне лечения препаратом «офтальмоферон» в зависимости от Noyabr, 2025-Yil 127 иммунного статуса пациентов. междисциплинарный подход по заболеваниям органов головы и шеи, 103. 3. ЖД, З., and А. БС. "РЕЗУЛЬТАТЫ ОЦЕНКИ УРОВНЯ ЭНДОТЕЛИНА-1 И ДДИМЕРОВ В СЛЕЗНОЙ ЖИДКОСТИ У ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ." SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES 3.3 (2024): 300-307. 4. Zhalalova, D. Z. OCT angiography in the assessment of retinal and choreoretinal microcirculation in patients with uncomplicated arterial hypertension International Ophthalmological Congress IOC Tashkent 2021. 5. Zhalalova, D. Z. Evaluation of markers of endothelial dysfunction in tear fluid in patients with arterial hypertension. Journal of Biomedicine in Amaliet. Tashkent-2022, Volume No., No. WITH. 6. Жалалова, Д. З. (2021). Эндотелин-1 ва гомоцистеин даражасини артериал гипертензия фонида тур пардв узгаришларида эндотелиал дисфункциянинг маркерлари сифатида текшириш. Биомедицина ва амалиет журнали, 6(5), 203-210. 7. Jalalova, D., Axmedov, A., Kuryazov, A., & Shernazarov, F. (2022). Combined dental and eye pathology. Science and innovation, 1(8), 91-100. 8. Zhalalova, D. Z. (2022). Pulatov US MICROCIRCULATORY DISORDERS IN THE VASCULAR SYSTEM OF THE BULBAR CONJUNCTIVA WITH INITIAL MANIFESTATIONS OF INSUFFICIENT BLOOD SUPPLY TO THE BRAIN. European journal of molecular medicine, 2(5). 9. Жалалова, Д. З. (2021). ОКТ-ангиография при оценке сосудистого русла сетчатки и хориоидеи. Биология ва тиббиет муаммолари, 6(130), 211-216. 10. Жалалова, Д. З. (2022). Классификационые критерии изменений сосудов сетчатки при артериальной гипертензии. In Международная научная конференция Университетская наука: взгляд в будущее (pp. 56-64). 11. Долиев, М. Н., Тулакова, Г. Э., Кадырова, А. М., Юсупов, З. А., & Жалалова, Д. З. (2016). Эффективность комбинированного лечения пациентов с центральной серозной хориоретинопатией. Вестник Башкирского государственного медицинского университета, (2), 64-66. 12. Жалалова, Д. З. Оценка маркеров эндотелиальной дисфункции в слезной жидкости у пациентов с артериальной гипертензиейЖурнал «Биомедицина ва амалиет». Тошкент-2022, Том №, №. С. 13. Жалалова, Д. З. (2021). ОКТ-ангиография в оценке ретинальной и хореоретинальной микроциркуляции у пациентов с неосложненой артериальной гипертензией/I Международный офтальмологческий конгресс IOC Uzbekistan, 2021 г. Ташкент, с, 96. 14. Shernazarov, F., Jalalova, D., Azimov, A., & CAUSES, S. A. (2022). SYMPTOMS, APPEARANCE, TREATMENT OF VARICOSE VEINS. 15. Жалалова, Д. З. (2021). Эндотелин-1 ва гомоцистеин даражасини артериал гипертензия фонида тур пардв узгаришларида эндотелиал дисфункциянинг маркерлари сифатида текшириш. Биомедицина ва амалиет журнали, 6(5), 203-210. Noyabr, 2025-Yil 128 16. Shernazarov, F., Tohirova, J., & Jalalova, D. (2022). Types of hemorrhagic diseases, changes in newboens, their early diagnosis. Science and innovation, 1(D5), 16-22. 17. Zhalalova, D. Z. (2022). The content of endothelin and homocysteine in blood and lacrimal fluid in patients with hypertensive retinopathy Web of Scientist: International Scientific Research Journal. ISSUE, 2, 958-963. 18. Shernazarov, F., & Zuhridinovna, J. D. (2022). Microcirculation disorders in the vascular system of the bulbar conjunctiva in the initial manifestations of cerebral blood supply deficiency. Science and innovation, 1(Special Issue 2), 515-522. 19. Zhalalova, D. Z. (2022). Modern aspects of neuroprotektive treatment in hypertensive retinopathy Web of Scientist: International Scientific Research JournalVolume 3. ISSUE, 2, 949-952. 20. Жалалова, Д. З. (2009). Метод комбинированного лечения диабетической ретинопатии. Врач-аспирант, 37(10), 864-868. 21. Жалалова, Д. З. (2023). Результаты оценки эффективности комплексного лечения у пациентов с 3-4 стадиями гипертонической ангиоретинопатии. Miasto Przyszłości, 41, 33-36. 22. ЖД, З., & ИЖ, Ж. (2024). КЛАССИФИКАЦИЯ ГИПЕРТОНИЧЕСКОЙ РЕТИНОПАТИИ НА ОСНОВЕ ДАННЫХ ОПТИЧЕСКОЙ КОГЕРЕНТНОЙ ТОМОГРАФИИ. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES, 3(3), 336-342. 23. ЗЖД, Ж. (2024). КЛИНИКО-ФУНКЦИОНАЛЬНЫЕ ПОКАЗАТЕЛИ ОРГАНА ЗРЕНИЯ У ПАЦИЕНТОВ С ИШЕМИЧЕКИМИ ИЗМЕНЕНИЯМИ СОСУДОВ СЕТЧАТКИ. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES, 3(3), 286-293. 24. ЖД, З. (2024). ОЦЕНКА КЛИНИЧЕСКИХ И ФУНКЦИОНАЛЬНЫХ ПОКАЗАТЕЛЕЙ ЭНДОТЕЛИАЛЬНОЙ ДИСФУНКЦИИ В СЛЕЗНОЙ ЖИДКОСТИ У ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES, 3(3), 330-335. 25. Жалалова, Д. З. (2023). Актуальность проблемы изменений глазного дна при артериальной гипертензии. Miasto Przyszłości, 41, 37-40.